HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon Is On Track After Q1 To Meet $200 Mil. EBITDA Target – Stahl

This article was originally published in The Rose Sheet

Executive Summary

Revlon is on target to deliver its EBITDA objective of $200 mil. in 2004, President and CEO Jack Stahl said during a first quarter sales and earnings presentation April 29. "Our objectives continue to be centered around strengthening our brands and restoring growth, building strong retail partnerships and strengthening and building the Revlon organization," the exec said

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel